PP及TP方案治疗晚期NSCLC的临床观察

Clinical Study of Paclitaxel/Cisplatin and Docetaxel/Cisplatin Regimens in the Treatment of Andvanced NSCLC

目的:比较紫杉醇与多西紫杉醇分别联合DDP治疗晚期NSCLC的临床疗效和毒副作用。方法:将我院108例不能手术的Ⅲ期～Ⅳ期NSCLC患者分组,接受PP方案或TP方案化疗,2个周期后评价疗效。PP组53例,TP组55例。结果:PP组有效率为43.39%,部分缓解率为39.62%,TP组有效率为47.27%,部分缓解率为41.82%,两组近期疗效比较差异无统计学意义(P>0.05)。PP组Ⅲ度～Ⅳ度白细胞下降30例(56.6%),TP组仅18例(32.72%),两组比较差异有统计学意义(P<0.05);Ⅲ度～Ⅳ度过敏反应在PP为8例(15.09%),TP组仅为2例(3.64%),差异有统计学意义(P<0.05);PP组发生神经毒性37例(69.81%),TP组有48例(87.27%),差异有统计学意义(P<0.05)。结论:PP方案与TP方案是治疗晚期NSCLC较有效的方案,疗效相似,PP方案神经毒性较轻,而过敏反应及血液学毒性反应发生率较高。

Objective： To compare the efficacy and toxicity of paclitaxel/cisplatin and docetaxel/cisplatin regimens in the treatment of advanced NSCLC. Methods ： One hundred and eight inoperatable patients with stageⅢtoⅣ NSCLC were randomized into PP（paclitaxel/cisplatin） and TP（docetaxel/cisplatin） group. All patients were treated for two cycles. 53 patients were in PP group, 55 patients in TP group. Results： The overall response rate were 43.39% and 47.27% ,the partial response rate were 39.62% and 41.82% in PP group and TP group respectively. No significant difference was observed（P 〉0.05）. The major side effects were leukopenia , anaphylaxis and neurotoxicity. 30 patients in PP group and 18 patients in TP group had grade Ⅲ-Ⅳleucopenia（P 〈 0.05 ）. 8 patients in PP group and 2 patients in TP group had grade Ⅲ-Ⅳ anaphylaxis （ P 〈 0.05 ）. 37 patients in pp group and 48 patients in TP group had neurotoxicity（P 〈 0.05）. Conclusion： Both PP and TP regimens are effective for advanced NSCLC. PP regimen has less neurotoxicity but higher myelosuppression and anaphylaxis.